Prostate cancer: ultrahypofractionated radiotherapy safe, effective in long term

  • Macias VA & al.
  • BJU Int
  • 15 Oct 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • 5-year study shows 8-fraction ultrahypofractionated radiotherapy is safe and has low relapse rate in patients with unfavorable intermediate-/high-risk prostate cancer.

Why this matters

  • Limited data are available on ultrahypofractionated radiotherapy in unfavorable intermediate-risk patients.

Study design

  • Phase 2 study of 154 patients with prostate cancer treated with ultrahypofractionated radiotherapy (43.8-45.2 Gy in 8 fractions over 3 weeks).
  • Funding: Castilla-Leon Public Health Service.

Key results

  • 73% of patients received androgen deprivation therapy.
  • 92 patients had unfavorable intermediate-/high-risk disease.
  • Median follow-up duration was 48 months.
  • 5-year biochemical disease-free survival was 94.3% overall and 90% in unfavorable intermediate-/high-risk patients.
  • In unfavorable intermediate-/high-risk patients, 5-year cumulative incidence of metastasis was 2.7%.
  • 5-year cumulative grade 2-3 genitourinary toxicity was 17.8% and gastrointestinal toxicity was 7.4%.
  • 1 patient experienced late grade 3 dysuria; no grade 4-5 toxicity was reported.

Limitations

  • Single group.